心肾缓衰方对慢性肾脏病合并心力衰竭患者心肾功能的作用及代谢组学研究
Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by
Xinshen Huanshuai Formula - 北京中医药 2025年44卷第9期 页码：1099-1105
- 作者机构：
1.中国中医科学院广安门医院肾病科，北京100053
2.中国中医科学院广安门医院生物样本库，北京100053
- 作者简介：
刘晨璇，女，27岁，博士研究生，医师。研究方向：中西医结合防治慢性肾脏病。
赵宇，E-mail：doctorwang0530@sina.com
- 基金信息：国家自然科学基金资助项目(81973683);国家自然科学基金青年科学基金项目(82104666);中国中医科学院科技创新工程项目(CI2023C051YLL);中国中医科学院优秀青年科技人才培养专项（创新类）(ZZ15-YQ-025)
DOI：10.16025/j.1674-1307.2025.09.003
中图分类号：收稿：2025-07-17，
修回：2025-10-24，
录用：2025-10-28，
纸质出版：2025-09-25
- 稿件说明：
移动端阅览
刘晨璇，路晓光，郑利华，等.心肾缓衰方对慢性肾脏病合并心力衰竭患者心肾功能的作用及代谢组学研究［J］.北京中医药，2025，44（9）：1099-1105.
LIU Chenxuan,LU Xiaoguang,ZHENG Lihua,et al.Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by Xinshen Huanshuai Formula[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(09):1099-1105.
刘晨璇，路晓光，郑利华，等.心肾缓衰方对慢性肾脏病合并心力衰竭患者心肾功能的作用及代谢组学研究［J］.北京中医药，2025，44（9）：1099-1105. DOI： 10.16025/j.1674-1307.2025.09.003.
LIU Chenxuan,LU Xiaoguang,ZHENG Lihua,et al.Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by Xinshen Huanshuai Formula[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(09):1099-1105. DOI： 10.16025/j.1674-1307.2025.09.003.
摘要
目的
2
通过自身前后对照研究观察临床验方心肾缓衰方改善慢性肾脏病合并心力衰竭（CKD-HF）患者心肾功能的临床疗效，并基于非靶向代谢组学比较经治肾功能改善预后不同人群的基线代谢组学差异。
方法
2
选取2023年6月—2023年12月就诊于中国中医科学院广安门医院肾病科门诊的CKD-HF患者36例，在西医常规一体化治疗的基础上，予心肾缓衰方治疗12周，收集患者估算肾小球滤过率（eGFR）、氨基末端脑钠肽前体（NT-proBNP）等理化指标，并比较中医证候积分和明尼苏达生活质量量表评分，以进行客观和主观疗效评价，同时基于超高效液相色谱串联质谱（UHPLC/MS）代谢组学分析临床队列中16例（每组8例）经治肾功能改善预后不同患者的基线代谢差异。
结果
2
共有33例患者完成随访，经心肾缓衰方治疗后eGFR改善（
P
<
0.01），其改善总有效率为69.70%；NT-proBNP、明尼苏达生活质量评价积分下降（
P
<
0.05，
P
<
0.01），中医证候积分下降（
P
<
0.01），其改善总有效率为72.73%；对血清样本进行非靶向代谢组学分析，筛选得到37种差异性代谢物，结果显示色氨酸、精氨酸等氨基酸代谢物及不饱和游离脂肪酸、中链酰基肉碱等脂质与CKD-HF不良预后相关，进一步通过差异性代谢物通路富集阐述CKD-HF生理病理机制，分析发现CKD-HF经治肾功能改善预后不同患者中脂肪酸生物合成等12条通路异常。
结论
2
心肾缓衰方对改善CKD-HF患者的心肾功能具有积极意义，能延缓肾功能进展，改善临床症状，提高患者生活质量，同时预后不同人群的基线氨基酸、脂质等代谢差异明显，其中脂肪酸生物合成通路显著富集。
Abstract
Objective
2
To observe the clinical efficacy of
Xinshen Huanshuai Formula
in improving cardiac and renal function in patients with chronic kidney disease complicated by heart failure （CKD-HF） through a self-controlled study， and to compare baseline metabolomic differences in patients with different renal prognoses using non-targeted metabolomics.
Methods
2
Thirty-six CKD-HF patients who attended the Department of Nephrology at Guang'anmen Hospital， China Academy of Chinese Medical Sciences， from June to December 2023， were enrolled. On the basis of standard integrated Western therapy， all patients received
Xinshen Huanshuai Formula
for 12 weeks. Clinical outcomes were assessed by physicochemical indicators such as estimated glomerular filtration rate （eGFR） and N-terminal pro
-B-type natriuretic peptide （NT-proBNP）， traditional Chinese medicine （TCM） syndrome scores， and Minnesota Living with Heart Failure Questionnaire （MLHFQ） scores to provide objective and subjective evaluations. Metabolomic profiling using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry （UHPLC-MS/MS） was performed on baseline serum samples from 16 patients （8 per group） stratified by renal prognosis to analyze metabolic differences.
Result
2
Thirty-three patients completed follow-up. After 12 weeks of treatment with
Xinshen Huanshuai Formula
， eGFR significantly improved （
P
<
0.01）， with a total effective response rate of 69.70%. NT-proBNP and MLHFQ scores decreased significantly （
P
<
0.05 and
P
<
0.01， respectively）， and TCM syndrome scores also decreased （
P
<
0.01）， with a total effective rate of 72.73%. Non-targeted metabolomics analysis identified 37 differential metabolites. Amino acid metabolites， including tryptophan and arginine， as well as lipids such as unsaturated free fatty acids and medium-chain acylcarnitines， were associated with poor CKD-HF prognosis. Pathway enrichment analysis revealed 12 dysregulated pathways， including fatty acid biosynthesis， reflecting the underlying pathophysiological mechanisms of CKD-HF in patients with different renal prognoses.
Conclusion
2
Xinshen Huanshuai Formula
effectively improves cardiac and renal function in CKD-HF patients， delays renal function deterioration， alleviates clinical symptoms， and enhances quality of life. Significant baseline differences in amino acid and lipid metabolism exist between patients with different renal prognoses， with marked enrichment of the fatty acid biosynthesis pathway.
关键词
Keywords
references
Kidney Disease : Improving Global Outcomes (KDIGO) CKD Work Group . KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [J ] . Kidney Int , 2024 , 105 ( 4S ): 117 - 314 .
Chronic Kidney Disease Prognosis Consortium , MATSUSHITA K , VAN DER VELDE M , et al . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis [J ] . Lancet , 2010 , 375 ( 9731 ): 2073 - 2081 .
MATSUSHITA K , BALLEW SH , WANG AY , et al . Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease [J ] . Nat Rev Nephrol , 2022 , 18 ( 11 ): 696 - 707 .
RONCO C , HAAPIO M , HOUSE AA , et al . Cardiorenal syndrome [J ] . J Am Coll Cardiol , 2008 ; 52 ( 19 ): 1527 - 1539 .
WANNER C , AMANN K , SHOJI T . The heart and vascular system in dialysis [J ] . Lancet , 2016 , 388 ( 10041 ): 276 - 284 .
张健 , 张宇辉 , 周蕾 . 国家心力衰竭指南2023（精简版） [J ] . 中国循环杂志 , 2023 , 38 ( 12 ): 1207 - 1238 .
陈可冀 , 吴宗贵 , 朱明军 , 等 . 慢性心力衰竭中西医结合诊疗专家共识 [J ] . 中国中西医结合杂志 , 2016 , 36 ( 2 ): 133 - 141 .
何立群 . 慢性肾衰竭的诊断、辨证分型及疗效评定(试行方案) [J ] . 上海中医药杂志 , 2006 ( 8 ): 8 - 9 .
郑筱英 . 中药新药临床研究指导 [M ] . 北京 : 中国医药科技出版社 , 2002 .
赵宇 , 占永立 , 饶向荣 , 等 . 460例慢性肾功能衰竭患者中医证候特征分析 [J ] . 中医杂志 , 2009 , 50 ( 5 ): 446 - 448 .
袁钟瑜 , 谢惠迪 , 杜青 , 等 . 慢性肾脏病审因论治探析 [J ] . 北京中医药 , 2021 , 40 ( 11 ): 1225 - 1228 .
刘璐 , 吴旸 , 崔杰 , 等 . 中老年心肾综合征患者中医证候要素研究 [J ] . 北京中医药 , 2017 , 36 ( 12 ): 1106 - 1108 .
ZAKROCKA I , ZAŁUSKA W . Kynurenine pathway in kidney diseases [J ] . Pharmacol Rep , 2022 , 74 ( 1 ): 27 - 39 .
PAWLAK K , MYSLIWIEC M , PAWLAK D . Haemostatic system,biochemical profiles,kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients [J ] . Thromb Res , 2010 ; 125 ( 2 ): e40 - e45 .
PEDERSEN ER , TUSETH N , EUSSEN SJ , et al . Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris [J ] . Arterioscler Thromb Vasc Biol , 2015 , 35 ( 2 ): 455 - 462 .
LIU JJ , CHING J , WEE HN , et al . Plasma tryptophan-kynurenine pathway metabolites and risk for progression to end-stage kidney disease in patients with type 2 diabetes [J ] . Diabetes Care , 2023 , 46 ( 12 ): 2223 - 2231 .
TAKKAVATAKARN K , PHANNAJIT J , UDOMKARNJANANUN S , et al . Association between indoxyl sulfate and dialysis initiation and cardiac outcomes in chronic kidney disease patients [J ] . Int J Nephrol Renovasc Dis , 2022 , 15 : 115 - 126 .
BARRETO FC , BARRETO DV , LIABEUF S , et al . Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients [J ] . Clin J Am Soc Nephrol , 2009 , 4 ( 10 ): 1551 - 1558 .
HOU H , HORIKAWA M , NARITA Y , et al . Suppression of indoxyl sulfate accumulation reduces renal fibrosis in sulfotransferase 1a1-deficient mice [J ] . Int J Mol Sci , 2023 , 24 ( 14 ): 11329 .
LYU J , CHEN J , WANG M , YAN F . Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization [J ] . Aging (Albany NY) , 2020 , 12 ( 10 ): 9139 - 9150 .
KANG HM , AHN SH , CHOI P , et al . Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development [J ] . Nat Med , 2015 , 21 ( 1 ): 37 - 46 .
SZCZUKO M , KACZKAN M , MAŁGORZEWICZ S , et al . The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression [J ] . Lipids Health Dis , 2020 , 19 ( 1 ): 77 .
AFSHINNIA F , RAJENDIRAN TM , SONI T , et al . Impaired β-oxidation and altered complex lipid fatty acid partitioning with advancing CKD [J ] . J Am Soc Nephrol , 2018 , 29 ( 1 ): 295 - 306 .
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备18046208号-2
京公网安备 11010102006710号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：348175 今日访问量：1214